Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial

OBJECTIVE: To conduct the first adjuvant trial of imatinib mesylate for treatment of gastrointestinal stromal tumor (GIST). SUMMARY BACKGROUND DATA: GIST is the most common sarcoma. While surgical resection has been the mainstay of therapy for localized, primary GIST, postoperative tumor recurrence...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: DeMatteo, Ronald P., Ballman, Karla V., Antonescu, Cristina R., Corless, Christopher, Kolesnikova, Violetta, von Mehren, Margaret, McCarter, Martin D., Norton, Jeffrey, Maki, Robert G., Pisters, Peter W.T., Demetri, George D., Brennan, Murray F., Owzar, Kouros
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4041735/
https://ncbi.nlm.nih.gov/pubmed/23860199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/SLA.0b013e3182a15eb7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky